Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes

By sjmartinez • March 5, 2025

Mariette X, Borchmann S, Aspeslagh S, Szekanecz Z, Charles-Schoeman C, Schreiber S, Choy EH, Peyrin-Biroulet L, Schmalzing M, Tanaka Y, Ten Cate H, Westhovens R, van der Woude CJ, Ekoka Omoruyi EV, Faes M, Masior T, Van Hoek P, Watson C, Rudolph C, Stallmach A. Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes. RMD Open. 2025 Mar 4;11(1):e005033. doi: 10.1136/rmdopen-2024-005033. PMID: 40037922; PMCID: PMC11881192.

Tags: Antirheumatic Agents, Arthritis, Inflammation, Publications, Rheumatoid, Rheumatology

American Society of Hematology 2026 guidelines for management of relapsed/refractory acute lymphoblastic leukemia in adolescents and young adults

O'Dwyer K, Winestone LE, Cheung MC, Benitez L, Buldini B, Cole PD, Damlaj M, Dholaria B, Dias AL, Dils A, Fritsch M, Greer J, Hayes-Lattin[...]

Quality measures in the design, conduct, and reporting of endoscopic research

Elmunzer BJ, Madhoun M, Cote GA, Cummings LC, Shahidi N, Srivastava N, Essex EA, Scheiman JM, May FP, Yen T, Barkun A, Durkalski-Mauldin V, Dominitz[...]

Premature Ventricular Contractions Ablated via the Left Ventricular Annular Vein: Demonstration of 3 Possible Approaches

Kanzaki Y, Morishima I, Mori S, Shimojo K, Tanaka Y, Yamada T. Premature Ventricular Contractions Ablated via the Left Ventricular Annular Vein: Demonstration of 3[...]